Volume 87 Issue 22 | p. 15 | Concentrates
Issue Date: June 1, 2009

Sanofi, Exelixis In Cancer Drug Pact

Department: Business
Keywords: Sanofi, Exelixis

Sanofi-Aventis and Exelixis are teaming up to develop drugs that block phosphoinositide-3 kinase (PI3K), a protein implicated in tumor growth as well as in cancer cell survival and resistance to chemotherapy and radiation. Sanofi gains access to two PI3K inhibitors in early-stage clinical trials. In exchange, Exelixis scores a $140 million up-front payment and $21 million in research funding over the course of the three-year pact. The South San Francisco-based biotech firm says it could eventually see up to $1 billion in milestone and royalty payments.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment